abrocitinib + baricitinib + upadacitinib

This is a combination of three oral Janus kinase (JAK) inhibitors: abrocitinib, baricitinib, and upadacitinib. Each drug selectively inhibits different members of the JAK family, which are intracellular enzymes involved in cytokine signaling via the JAK/STAT pathway. This pathway plays a central role in immune modulation and inflammation. Abrocitinib is primarily a selective JAK1 inhibitor; baricitinib inhibits both JAK1 and JAK2; upadacitinib is also more selective for JAK1 but can inhibit other isoforms at higher concentrations. All three drugs are approved or in advanced clinical development for moderate-to-severe atopic dermatitis and have demonstrated efficacy as monotherapy or with topical corticosteroids. They are also used individually for other inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. There is no evidence that this specific triple combination (abrocitinib + baricitinib + upadacitinib) has been developed or studied as a single pharmaceutical product.